Korea’s Hugel reported its highest-ever quarterly earnings on Wednesday, with operating profit climbing 33.6 percent year over year to 56.7 billion won ($40.8 million) in the second quarter of 2025. 

The company credited robust overseas demand for its botulinum toxin (BTX) and hyaluronic acid (HA) filler products for the surge.

Consolidated revenue rose 15.5 percent to 110.3 billion won ($81.3 million), while net income edged up 3.3 percent to 38.2 billion won. All three metrics marked quarterly records and pushed Hugel’s first-half sales past 200 billion won and operating profit beyond 95 billion won.

International sales accounted for 63 percent of the company’s second-quarter revenue, reaching 69.8 billion won, up 21 percent from the same period last year. Exports of BTX and filler products made up 73 percent of category sales in the quarter, driven by strong performance in the United States, China, and Europe.

BTX sales, under the brand names Botulax in Korea and Letybo globally, rose 20 percent to 61.2 billion won in the quarter, surpassing 100 billion won in cumulative first-half revenue.

The company pointed to additional U.S. shipments in June following Letybo’s commercial launch in March, along with continued growth in Asia-Pacific markets including China, Taiwan, and Australia.

HA filler sales reached 34.1 billion won for the quarter, bolstered by demand in APAC and European markets. Meanwhile, cosmetics brands such as WELLAGE and BYRYZN BR more than doubled sales year over year, posting 13.6 billion won in revenue.